23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
21:10 , May 25, 2018 |  BioCentury  |  Finance

Buyback Band-Aid

A $3 billion expansion of its share buyback program won’t help Celgene Corp. (NASDAQ:CELG) address the long-term pipeline problems that concern a trio of buysiders, who would rather see the big biotech put the spending...
22:51 , Apr 6, 2018 |  BioCentury  |  Finance

Picking season

  Macroeconomic risks, surging volatility and a tail-off in the M&A market since January have done little to change the buyside’s strategy of overweighting small- and mid-cap biotechs. In fact, the 12 investors who spoke...
00:43 , Mar 3, 2018 |  BioCentury  |  Finance

Rocky road

While a trio of buysiders who spoke with BioCentury believe sentiment toward Celgene Corp. will remain poor in the near term in the wake of a regulatory delay for ozanimod, they believe commercial success from...
22:36 , Feb 9, 2018 |  BioCentury  |  Finance

Elites always welcome

The fact that 69 biotechs have raised $6.1 billion via IPO financings on NASDAQ since the start of 2016 might suggest the IPO window has remained wide open in the U.S. A closer look at...
22:07 , Feb 2, 2018 |  BioCentury  |  Finance

Celgene sticks with the combo

While the market showed relative indifference to the appointment of CEO Mark Alles to the additional role of chairman of Celgene Corp. (NASDAQ:CELG), it goes against the trend among the big biotechs. On Jan. 29...
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
16:25 , Jan 26, 2018 |  BC Week In Review  |  Company News

Celgene acquiring Juno for $9B

Celgene Corp. (NASDAQ:CELG) said it will acquire Juno Therapeutics Inc. (NASDAQ:JUNO) for $87 per share, or about $9 billion. The price is a 28% premium to Juno's close of $67.81 on Jan. 19, before the...
02:22 , Jan 26, 2018 |  BC Extra  |  Company News

Celgene reports 4Q17 earns, expresses interest in M&A

Celgene Corp. (NASDAQ:CELG) reported fourth quarter earnings Thursday, including EPS that topped the Street's estimates, driven by U.S. sales of cancer drug Revlimid lenalidomide. On the heels of two acquisition deals this month, Celgene also...
23:56 , Jan 22, 2018 |  BC Extra  |  Company News

Celgene acquiring Juno for $9B

Celgene Corp. (NASDAQ:CELG) said it will acquire Juno Therapeutics Inc. (NASDAQ:JUNO) for $87 per share, or about $9 billion. The price is a 28% premium to Juno's close of $67.81 on Friday, before the deal...